

Parathyroid hormone - from treatment marker to treatment target

10TH EUROD WINTER MEETING PROGRAMME

JANUARY 20-22, 2027

Venue: Convent of Chièvres, Leuven, Belgium

AFFILIATED ENDORSED INITIATIVE

ERA
LEADING EUROPEAN NEPHROLOGY

ORGANISED BY

EUROD
European Renal Osteodystrophy

CKD-MBD
Chronic Kidney Disease Mineral and Bone Disorder

Wednesday, January 20, 2027

13:00 – 17:00 Clinical Hot Topics

Join us for an update on the assessment and treatment of bone and vascular disease in CKD, by state-of-the-art lectures on current topics in the fields of CKD-associated cardiovascular disease and osteoporosis.

Hot topics CKD-assocaited cardiovascular disease
Chairs: Smeeta Sinha & Antonio Bellasi

- **13:00 – 13:25 Best clinical papers on CKD-associated cardiovascular disease in 2026** *(Smeeta Sinha, Manchester University, United Kingdom)*

- **13:30 – 13:55 Predicting parathyroid gland responsiveness to medical therapy** *(Nahid Tabibzadeh, Paris, France)*

- **14:00 – 14:25 Dietary interventions to improve outcomes in CKD** *(Louise Salomo, Copenhagen, Denmark)*

14:30 – 15:30: Poster Session 1

Hot topics CKD-associated osteoporosis
Chairs: Hanne Skou Jørgensen & Maria Fusaro

- **15:30 – 15:55 EUROD Consensus 2026: CKD-associated osteoporosis after kidney transplantation** *(Pieter Evenepoel, Leuven, Belgium)*

- **16:00 – 16:25 Best clinical papers in (CKD-associated) osteoporosis 2026** *(Michael Laurent, Imelda, Belgium)*

- **16:30 – 16:55 Opportunistic screening for osteoporosis using clinical CT** *(Anna Spångeus, Linkøbing University, Sweden)*

18:30 Meet & Greet in Leuven

Thursday, January 21, 2027

09:00 – 10:30 Workshop: Tackling hyperparathyroidism before and after kidney transplantation. *The workshop addresses clinical issues through interactive, case-based discussions with experts in the field. Participants rotate between the two sessions, each of 40 minutes duration (to run twice).*

- **Room 1. Optimizing mineral metabolism before kidney transplantation** *(Carlo Alfieri, University of Milan, Italy & Fabrice Mac-Way, Montreal, Canada)*

- **Room 2. Treating mineral metabolism disturbances in kidney transplant recipients** *(Hege Philstrøm, Oslo University Hospital, Norway & Marc Vervloet, Nijmegen, The Netherlands)*

10:30 – 11:00 Coffee break

11:00 – 12:30 Symposium: Mineral metabolism and bone in rare diseases
Chairs: Agnieszka Prytula & Nathalie Bravenboer

- **11:00 – 11:20 Statural growth in children with tubulopathies**
(Detlef Böckenhauer, Leuven, Belgium)

- **11:25 – 11:45 Bone phenotype and related symptoms in XLH**
(Natasha Appelman-Dijkstra, Leiden, The Netherlands)

- **11:50 – 12:10 Bone and teeth: what the hospital doctor needs to know**
(To be confirmed)

12:15 – 13:30 Lunch

13:30 – 18:00: Research Forum
The EUROD research forum focuses on scientific progress in renal bone disease, inviting basic and clinical researchers to present their findings through a mixture of invited mini lectures, oral abstract communications, and short pitches, with ample time for discussion.

13:30 – 15:00: Research Forum part 1
Chairs: Marie-Helene Lafage-Proust & Anja Verhulst

- **13:30 – 13:50 (ML): What makes parathyroid hormone a bone anabolic therapy?**
(Lisbeth Koch Thomsen, University of South Denmark, Denmark)

- **13:55 – 14:05 (FC):** *To be confirmed*

- **14:10 – 14:20 (FC):** *To be confirmed*

- **14:25 – 14:35 (FC):** *To be confirmed*

- **14:35 – 14:50 (ML): Alkaline phosphatases – potential clinical implications in CKD**
(Dieter Smout, UZ Leuven, Belgium)

15:00 – 16:00: Poster Session 2

16:00 – 17:30: Research Forum part 2
Chairs: Nathalie Bravenboer & Ina Karstoft Ystrøm

- **16:00 – 16:20 (ML): Cortical bone in ageing and in CKD**
(Marie-Helene Lafage-Proust, St. Etienne, France)

- **16:25 – 16:35 (FC):** *To be confirmed*

- **16:40 – 16:50 (FC):** *To be confirmed*

- **16:55 – 17:15 (ML): The future of bone biopsies in CKD**
(Fabrice Mac-Way, Montreal, Canada)

17:15: Best Abstract Awards *(Pieter Evenepoel, KU Leuven, Belgium)*

19:00: Network Dinner *(De Optimist, Vismarkt 7, 3000 Leuven)*

Friday, January 22, 2027

09:00 – 10:00: Meet the professor
Ask all your practical questions to experts in the field. An informal session with Q&A.

- **Room 1: Should we use PTH, bone turnover markers, or both?**
(Etienne Cavalier, Liège, Belgium & Mathias Haarhaus, Copenhagen, Denmark)

- **Room 2: Sequential therapy in (CKD-associated) osteoporosis?**
(Bente Langdahl, Arhus, Denmark & Pieter Evenepoel, UZ Leuven, Belgium)

- **Room 3: How do we optimize bone imaging in clinical practice?**
(Marie-Helene Lafage-Proust, St. Etienne, France & Antoine Bouquegneau, Liege, Belgium)

10:00 – 10:45: Coffee break

10:45 – 14:00 CME: Parathyroid hormone – from treatment marker to treatment target
Parathyroid hormone (PTH) excess drives osteoporosis and cardiovascular disease in CKD. Our current guidelines recommend a broad target range for PTH at 2 to 9 times the assay upper normal limit, but this strategy has failed to improve clinical outcomes. Biochemical markers of bone turnover have been suggested as alternative or adjunct treatment targets for hyperparathyroidism in CKD. This CME will explore the current understanding of hyperparathyroidism and state-of-the-art diagnosis and treatment options, focusing on the shift from using PTH as a biomarker to instead considering end-organ effects of hyperparathyroidism as the main treatment targets in CKD.

10:45 – 11:00 Welcome *(Pieter Evenepoel, KU Leuven, Belgium)*

11:00 – 12:00 Session 1: Approach to hyperparathyroidism: the context matters
Chairs: Mathias Haarhaus & Marie-Helene Lafage-Proust

- **11:00 – 11:25 Hyperparathyroidism and bone: the endocrinologist's perspective**
(Stefan Pilz, Graz, Austria)

- **11:30 – 11:55 PTH, a key driver of CKD-associated CVD and osteoporosis?**
(Lorenza Magagnoli, Milan, Italy)

12.00 – 13:00 Lunch

13:00 – 14:00 Session 2: Approach to hyperparathyroidism: advances in therapy
Chairs: Maria Fusaro & Antonio Bellasi

- **13:00 – 13:25 Advances in parathyroid gland imaging and surgical technique**
(Lars Rolighed, Aarhus University, Denmark)

- **13:30 – 13:55 Novel therapeutic options: On-target and off-target effects**
(Marc Vervloet, Nijmegen, The Netherlands)

14:00 – 14:30 Networking break

14:30 – 15:45 Keynote lectures – a look towards the future
Chairs: Hanne Skou Jørgensen & Pieter Evenepoel

- **14:30 – 14:55 CKD-associated osteoporosis: How do we close the treatment gap?**
(Tom Nickolas, Washington University, United States)

- **15:00 – 15:25 Perspectives in osteoporosis: What is on the horizon?** *(Bente Langdahl, Aarhus University, Denmark)*

- **15:30 – 15:45 Panel discussion**

15:45 – 16:00 Concluding remarks *(Pieter Evenepoel, KU Leuven, Belgium)*

Saturday, January 23, 2027

08:00 – 15.30 Belgian Bone Club 2027 Clinical Update Symposium
(Brussels, separate registration necessary: https://www.bbcbonehealth.org)